Navigating Innovation & Research Opportunities (NIRO)
Helping actors in research and innovation identify opportunities within and beyond the European Union
Overview
NIRO is designed to help stakeholders from the private and public sector, not-for-profit organizations, and academia identify which research and innovation (R&I) initiatives and program opportunities could be the right fit. This tool includes initiatives and programs sponsored by the European Commission, as well as national ministries, agencies, and not-for-profit organizations within and beyond the European Union.
EFPIA, together with GSK, put together an interactive tool to navigate R&I funding opportunities at the national, EU, and global level. It includes over 50 opportunties in healthcare and the life sciences that could advance R&D in Europe and worldwide.
Explore Global Health Progress
Global Health Progress is an interactive knowledge hub highlighting over 250 collaborations in low- and middle-income countries between the innovative pharmaceutical industry and over 1100 diverse partners to support the SDGs.
Advancing opportunities in research and innovation
Discover R&I initiatives and program opportunities in healthcare and life sciences that might be the right fit for you.
Other partnerships and alliances
See all
The International Council for Harmonisation (ICH)
As a Standing Observer of ICH, IFPMA along with other ICH Members and Observers, has an important role in promoting global convergence toward ICH regulatory standards and their harmonized interpretation.
INTREPID Alliance
INTREPID Alliance exists to accelerate the development of new treatments for emerging viral pandemic agents through coordinated early science and R&D, policy and advocacy and stakeholder engagement. INTREPID Alliance members collectively bring expertise in drug discovery, antiviral R&D and medicine manufacturing.
BeCOME
BeCOME (Beyond COVID Monitoring Excellence) was initiated to create a sustainable forum where experts in pharmacovigilance and pharmacoepidemiology from industry, public health, regulators, and academia can collectively meet.